Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Characterization of a Pathogenic Variant in the ABCD1 Gene Through Protein Molecular Modeling
Richter, John E. , Vadlamudi, Charitha , Macklin, Sarah , Samreen, Ayesha , Helmi, Haytham , Broderick, Daniel F. , Mohammad, Ahmed N. , Hines, Stephanie L., VanGerpen, Jay A., Atwal, Paldeep S. , Macklin, Sarah K, Broderick, Daniel, Caulfield, Thomas R , Atwal, Paldeep S , Samreen, Ayesha , Caulfield, Thomas R.

Mayo Clinic

Case Reports in Genetics | January 25, 2020 | Volume: 2020 | Issue: No issue available | Pages: 1-7

10.1155/2020/3256539 | PMID 32047678 Get It

Background. The ATP-binding cassette, subfamily D, member 1 (ABCD1) protein is a peroxisomal half-transporter that allows for very long chain fatty acid (VLCFA) degradation. Pathogenic variants of ABCD1 cause VLCFAs to build up in various tissues and bodily fluids, resulting in a disorder called X-linked adrenoleukodystrophy (X-ALD). This disorder is most commonly marked by adrenocortical insufficiency and high VLCFA concentration, and has varying levels of neurological involvement depending on phenotype. For example, the Addison-only form of X-ALD has no neurological impact, while the cerebral form of X-ALD often causes severe sensory loss, motor function impairment, cognitive decline, and death. Methods. A newly characterized and suspected pathogenic variant in ABCD1 was analyzed using our protein informatics platform (PIP). Personalized protein-level molecular studies were completed on genetic testing data, complementing the analysis and clinical study. Results. A case of adult onset adrenomyeloneuropathy (AMN) and a novel ABCD1 variant are presented. The unique ABCD1 protein is discussed, and the proband’s case is compared to existing reports of AMN. Conclusions. Data fusion from multiple sources was combined in a comprehensive approach yielding an enriched assessment of the patient’s disease and prognosis. Molecular modeling was performed on the variant to better characterize its clinical significance and confirm pathogenicity.
The effects of climate change on human health in Africa, a dermatologic perspective: a report from the International Society of Dermatology Climate Change Committee
Coates, Sarah J. , Enbiale, Wendemagegn , Davis, Mark D.P., Andersen, Louise K. , Enbiale, Wendemagegne

Mayo Clinic

International Journal of Dermatology | January 23, 2020 | Volume: 59 | Issue: 3 | Pages: 265-278

10.1111/ijd.14759 | PMID 31970754 Get It

AbstractThroughout much of the African continent, healthcare systems are already strained in their efforts to meet the needs of a growing population using limited resources. Climate change threatens to undermine many of the public health gains that have been made in this region in the last several decades via multiple mechanisms, including malnutrition secondary to drought‐induced food insecurity, mass human displacement from newly uninhabitable areas, exacerbation of environmentally sensitive chronic diseases, and enhanced viability of pathogenic microbes and their vectors. We reviewed the literature describing the various direct and indirect effects of climate change on diseases with cutaneous manifestations in Africa. We included non‐communicable diseases such as malignancies (non‐melanoma skin cancers), inflammatory dermatoses (i.e. photosensitive dermatoses, atopic dermatitis), and trauma (skin injury), as well as communicable diseases and neglected tropical diseases. Physicians should be aware of the ways in which climate change threatens human health in low‐ and middle‐income countries in general, and particularly in countries throughout Africa, the world's lowest‐income and second most populous continent.
Responsiveness of a Balance Assessment Using a Mobile Application
Anderson, Sarah , Campbell, Graeme R., Davis, Samson J., Tindall, Samuel W., Anderson, Sarah E, Krause, David A. , Anderson, Sarah E., Hollman, John H.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | January 21, 2020 | Volume: 12 | Issue: 4 | Pages: 401-404

10.1177/1941738119888656 | PMID 31961240 Get It

Background: Balance assessment is used by clinicians as part of athlete concussion screening. The King-Devick (K-D) Balance app is designed to provide an objective balance assessment value. The purpose of this study was to investigate the responsiveness of a balance assessment using the K-D Balance app. Hypothesis: The K-D Balance app will demonstrate acceptable responsiveness for balance assessment. Study Design: Repeated-measures study. Level of Evidence: Level 5. Methods: A convenience sample of 25 participants between the ages of 20 and 25 years completed testing procedures. A battery of balance tests using the K-D Balance app on an iPhone were conducted 1 week apart. After a 5-minute warm-up, 3 stances were assessed: double leg, tandem right, and tandem left. The K-D Balance app guided the test positions and test times. A value representing movement was generated by the app algorithm. Analysis included descriptive statistics along with intraclass correlation coefficient and minimal detectable change (MDC). Results: The median score of the K-D test was 0.5 for session 1 and 0.4 for session 2. The ICC was 0.42 (95% CI, 0.04-0.70), and the MDC was 1.58. Conclusion: The MDC value of 1.58 represents the threshold of meaningful change in balance, as measured with the K-D Balance app. Clinical Relevance: Clinicians can use the results of this study to objectively assess changes in balance over time using the K-D Balance app.
Ki-67 Labeling Index in Pulmonary Carcinoid Tumors: Comparison Between Small Biopsy and Resection Using Tumor Tracing and Hot Spot Methods
Kroneman, Trynda, Jenkins, Sarah M. , Terra, Simone , Molina, Julian R. , Mounajjed, Taofic, Roden, Anja C. , Boland, Jennifer M. , Kroneman, Trynda N, Terra, Simone B S P, Molina, Julian, Xie, Hao

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 16, 2020 | Volume: 144 | Issue: 8 | Pages: 982-990

10.5858/arpa.2019-0374-oa | PMID 31944862 Get It

Context.— Pulmonary carcinoids are classified as typical or atypical by assessing necrosis and mitoses, which usually cannot be adequately assessed on small biopsies. Ki-67 is not currently used to grade pulmonary carcinoids, but it may be helpful to determine preliminary grade in biopsies. However, the rate at which Ki-67 could underestimate or overestimate grade on small biopsies has not been well studied. Objective.— To compare Ki-67 labeling obtained on small biopsies to subsequent resection. Design.— Ki-67 was performed on paired biopsy and resection specimens from 55 patients. Slides were scanned using Aperio ScanScope. Labeling index was determined using automated hot spot and tumor tracing methods. Results.— The study included 41 typical and 14 atypical carcinoids. Atypical carcinoids were larger and had more distant metastases. Death from disease occurred in 3 patients (all had atypical carcinoids). Median hot spot Ki-67 labeling index was greater in resection compared with biopsy by 0.7% (P = .02). Median tumor tracing Ki-67 was lower in resection compared with biopsy by 0.5% (P < .001). Receiver-operating characteristic analysis showed similar hot spot Ki-67 cutoffs to predict atypical histology (3.5% for biopsy, 3.6% for resection; area under the curve [AUC], 0.75 and 0.74, respectively). Different optimal cutoffs were needed for tracing method based on biopsy (2.1%; AUC, 0.75) compared with resection (1.0%; AUC, 0.67). Conclusions.— Hot spot Ki-67 tends to underestimate grade on small biopsies, whereas grade is overestimated by tumor tracing. Hot spot Ki-67 cutoff of 3.5% predicted atypical histology for both biopsy and resection. Different biopsy and resection cutoffs were necessary for tumor tracing, which would make clinical implementation more difficult.
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN)
Aschenbrenner, Andrew J. , James, Bryan D. , Wang, Guoqiao , Lim, Yen Ying , Benzinger, Tammie L.S. , Cruchaga, Carlos , Goate, Alison , Xiong, Chengjie , Perrin, Richard J. , Buckles, Virginia, Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , O’Connor, Antoinette , Graff‐Radford, Neill R. , Gräber, Susanne, Martins, Ralph N. , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Hassenstab, Jason , Network, Dominantly Inherited Alzheimer, Cruchaga, Carlos , O'Connor, Antoinette , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Benzinger, Tammie L S , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , McDade, Eric , Xiong, Chengjie , Allegri, Ricardo , Ghetti, Bernardino , Goldman, Jill , Karch, Celeste M. , Lee, Jae‐Hong , Schofield, Peter R. , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 219-228

10.1002/alz.12010 | PMID 31914221 Get It

AbstractIntroductionAlthough some members of families with autosomal dominant Alzheimer's disease mutations learn their mutation status, most do not. How knowledge of mutation status affects clinical disease progression is unknown. This study quantifies the influence of mutation awareness on clinical symptoms, cognition, and biomarkers.MethodsMutation carriers and non‐carriers from the Dominantly Inherited Alzheimer Network (DIAN) were stratified based on knowledge of mutation status. Rates of change on standard clinical, cognitive, and neuroimaging outcomes were examined.ResultsMutation knowledge had no associations with cognitive decline, clinical progression, amyloid deposition, hippocampal volume, or depression in either carriers or non‐carriers. Carriers who learned their status mid‐study had slightly higher levels of depression and lower cognitive scores.DiscussionKnowledge of mutation status does not affect rates of change on any measured outcome. Learning of status mid‐study may confer short‐term changes in cognitive functioning, or changes in cognition may influence the determination of mutation status.
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, Boris , Anderson, Stacey M. , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Buckingham, Bruce A. , Doyle, Francis J. , Brown, Sue A. , Church, Mei Mei , Dadlani, Vikash, Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P. , Isganaitis, Elvira , Lam, David W. , Lum, John W. , Group, iDCL Study, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Schultz, Alan , Kim, Kenny, Church, Mei Mei, André, Camille , Lam, David W., O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Simha, Vinaya , McCrady-Spitzer, Shelly , Reid, Corey, Jost, Emily , Berget, Cari , Towers, Lindsey, Buckingham, Bruce, Ekhlaspour, Laya, Hsu, Liana, Loebner, Sarah E., Doyle, Francis J., Campos, Tiffany, Passman, Samantha, Murphy, Carlos, Patibandla, Nandan, Kollman, Craig, Pinsker, Jordan E , Doyle, Francis J , Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P , Lum, John , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Wadwa, R Paul , Beck, Roy W. , Group, iDCL Study, Oliveri, Mary Clancy , Church, Mei Mei, Lam, David W., Messer, Laurel H , Buckingham, Bruce, Ekhlaspour, Laya, Doyle, Francis J., Kollman, Craig

Mayo Clinic

Diabetes Care | January 15, 2020 | Volume: 43 | Issue: 3 | Pages: 607-615

10.2337/dc19-1310 | PMID 31937608 Get It

OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P < 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P < 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, Kristin A. , Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Diver, W. Ryan , Hennis, Anselm , Nemesure, Barbara , Klein, Eric A. , Rybicki, Benjamin A. , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Stephens, Owen , Zangari, Maurizio , Hu, Jennifer J. , Nyante, Sarah J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Tomasson, Michael H. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Chiu, Brian C.‐H. , Ziv, Elad , Vij, Ravi , Bernal‐Mizrachi, Leon , Morgan, Gareth J. , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Conti, David V. , Haiman, Christopher A. , Orlowski, Robert Z. , John, Esther M , Klein, Eric A , Nyante, Sarah , Morgan, Gareth J , Ziv, Elad , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Bernstein, Leslie , Rhee, Frits van , Olshan, Andrew F. , Zheng, Wei , Ziegler, Regina G. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Stram, Daniel O. , Lonial, Sagar , Cozen, Wendy

Mayo Clinic

Blood Advances | January 14, 2020 | Volume: 4 | Issue: 1 | Pages: 181-190

10.1182/bloodadvances.2019000491 | PMID 31935283 Get It

Abstract Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of EA. Little is known about genetic risk factors for MM in individuals of AA. We performed a meta-analysis of 2 GWASs of MM in 1813 cases and 8871 controls and conducted an admixture mapping scan to identify risk alleles. We fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. In GWAS meta-analysis, we identified 2 suggestive novel loci located at 9p24.3 and 9p13.1 at P < 1 × 10−6; however, no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. Of the 23 known EA risk variants, 20 showed directional consistency, and 9 replicated at P < .05 in AA individuals. In 8 regions, we identified markers that better capture MM risk in persons with AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95% confidence interval, 1.56-2.11) increased MM risk compared with those with average risk (25%-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P = 5.1 × 10−12). Our study shows that common genetic variation contributes to MM risk in individuals with AA.
Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant
Ibrahim, Samar H. , Jonas, Maureen M. , Taylor, Sarah A. , Sanchez, Luz Helena Gutierrez , Wolf, Jaqueline L., Sundaram, Shikha S. , Sanchez, Luz Helena Gutierrez , Ibrahim, Samar H , Gutierrez Sanchez, Luz Helena

Mayo Clinic

Hepatology | January 11, 2020 | Volume: 71 | Issue: 4 | Pages: 1474-1485

10.1002/hep.31109 | PMID 31925801 Get It

Liver diseases affecting the mother and infant dyad may present in the perinatal period from 20 weeks of gestation to 28 days of life. This review will focus on the current approach to neonatal acute liver failure and the progress made in the diagnosis and management of gestational alloimmune liver disease. It will highlight mother‐to‐child transmission of viral hepatitis, both management and public health implications. Emerging concepts implicating maternal obesity and nutrition in the development of a rapidly progressive nonalcoholic steatohepatitis phenotype in the offspring will be discussed. Finally, the presentation and management of acute fatty liver of pregnancy and intrahepatic cholestasis of pregnancy, and their impact on the fetus, will be reviewed.